Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Alexion Pharmaceuticals will acquire the Boston-based biotech firm Syntimmune for $400 million plus up to $800 million in potential milestone payments. Syntimmune says its lead antibody drug candidate, SYNT001, has the potential to treat autoimmune disease by facilitating the destruction of human immunoglobulin G antibodies that cause the disease. SYNT001 is already undergoing testing in people with a rare autoimmune blistering disease called pemphigus and a rare form of autoimmune anemia.
This article has been sent to the following recipient: